Want to see JP:4694 full AI Analyst Report?
Top Page
BML
(4694)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥3,648.00
▼(-4.38% Downside)
Action:Downgraded
Date:05/15/26
The score is primarily supported by strong financial stability (low leverage) and a constructive recent rebound in earnings/cash flow, but is held back by clearly weak technical momentum (below major moving averages, negative MACD) and only moderate valuation support despite a solid dividend yield.
Positive Factors
Strong Balance Sheet
Very low leverage and a large equity base provide durable financial flexibility. This solvency allows the company to fund R&D, capex or acquisitions, absorb cyclical shocks and avoid refinancing stress, supporting long-term stability and strategic optionality.
Negative Factors
Revenue & Margin Volatility
Significant multi-year volatility in sales and margins reduces predictability of earnings and planning. Structural demand swings or competitive pressures that caused earlier declines could re-emerge, limiting visibility for investment decisions and long-term margin recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Balance Sheet
Very low leverage and a large equity base provide durable financial flexibility. This solvency allows the company to fund R&D, capex or acquisitions, absorb cyclical shocks and avoid refinancing stress, supporting long-term stability and strategic optionality.
Read all positive factors
BML (4694) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥134.25B
Dividend Yield3.48%
Average Volume (3M)54.09K
Price to Earnings (P/E)17.0
Beta (1Y)0.31
Revenue Growth3.88%
EPS Growth26.78%
CountryJP
Employees4,612
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)203.84
Shares Outstanding40,749,428
10 Day Avg. Volume38,460
30 Day Avg. Volume54,093
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)1.21
Price to Sales (P/S)1.02
P/FCF Ratio12.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,800.00Price Target Upside-0.39% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)222.3
Revenue Forecast (FY)¥157.00B
BML Business Overview & Revenue Model
Company Description
BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized ...
How the Company Makes Money
null...
BML Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
88
Very Positive
Cash Flow
62
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 150.26B | 143.19B | 137.96B | 159.46B | 186.07B |
| Gross Profit | 48.69B | 45.86B | 45.63B | 61.45B | 86.95B |
| EBITDA | 21.23B | 17.51B | 16.42B | 30.57B | 56.26B |
| Net Income | 7.75B | 6.26B | 6.04B | 15.58B | 33.74B |
Balance Sheet | |||||
| Total Assets | 183.25B | 177.99B | 171.46B | 169.27B | 179.59B |
| Cash, Cash Equivalents and Short-Term Investments | 68.03B | 67.56B | 74.11B | 86.52B | 92.13B |
| Total Debt | 4.82B | 5.29B | 5.26B | 4.16B | 3.35B |
| Total Liabilities | 51.12B | 44.21B | 41.32B | 42.52B | 57.91B |
| Stockholders Equity | 127.67B | 129.40B | 125.87B | 122.49B | 116.20B |
Cash Flow | |||||
| Free Cash Flow | 11.96B | 663.00M | -4.57B | 7.18B | 39.91B |
| Operating Cash Flow | 20.71B | 15.81B | 14.45B | 11.74B | 45.60B |
| Investing Cash Flow | -7.69B | -16.79B | -21.14B | -7.63B | -7.30B |
| Financing Cash Flow | -12.35B | -5.43B | -5.73B | -9.71B | -9.83B |
BML Technical Analysis
Neutral
3815.00
Price Trends
3600.80
Negative
3715.09
Negative
3760.17
Negative
Market Momentum
-23.50
Positive
50.10
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4694, the sentiment is Neutral. The current price of 3815 is above the 20-day moving average (MA) of 3594.00, above the 50-day MA of 3600.80, and above the 200-day MA of 3760.17, indicating a bearish trend. The MACD of -23.50 indicates Positive momentum. The RSI at 50.10 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4694.
BML Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ¥61.20B | 11.64 | ― | 2.79% | 1.72% | 6.07% | |
63 Neutral | ¥134.25B | 17.04 | 6.11% | 3.34% | 3.88% | 26.78% | |
58 Neutral | ¥166.92B | 17.90 | 0.33% | 3.73% | 3.04% | -19.26% | |
57 Neutral | ¥73.06B | 20.63 | ― | 2.28% | 2.94% | 57.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4694
BML
3,590.00
215.07
6.37%
JP:6523
PHC Holdings Corp.
1,311.00
365.34
38.63%
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,470.00
77.75
5.58%
JP:4549
Eiken Chemical Co., Ltd.
2,216.00
-52.25
-2.30%
BML Corporate Events
BML Grants Long-Term Restricted Stock to Executives to Align Pay With Shareholder Value
Jul 24, 2026
BML, Inc. has approved the disposal of 19,466 treasury shares as restricted stock compensation to six directors and ten executive officers, valued at approximately ¥68.9 million at a price of ¥3,540 per share. The shares are allocated un...
BML Reshapes Top Management as Representative Director Retires
May 13, 2026
BML, Inc. announced that Representative Director and Vice-President Nobuki Arai will retire from his role as Representative Director when his term as Director expires on June 26, 2026, while continuing in key positions at PCL Japan, Inc. and BML G...
BML Raises Year-End Dividend After Beating Earnings Forecasts
May 13, 2026
BML, Inc. has approved an increase in its year-end dividend for the fiscal year ended March 31, 2026, raising the payout to 65 yen per share from the previously forecast 60 yen. The total annual dividend for FY2026 will be 125 yen per share, up fr...
BML lifts earnings and dividend on solid FY2025 results, guides cautiously for FY2026
May 13, 2026
BML, Inc. reported solid results for the fiscal year ended March 31, 2026, with net sales rising 4.9% to ¥150.3 billion and profit attributable to owners of parent climbing 23.7% to ¥7.7 billion, lifting basic earnings per share to ¥...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.